Shigella Vaccines MarketSize and Trends

Joint ventures and collaborations of major players to develop and commercializes the vaccine are expected to propel the Shigella vaccines market in near future

Joint ventures and partnership of the players to develop and commercialize Shigella vaccine is expected to provide momentum to the Shigella vaccines market. For instance, in October 2019, The European Vaccine Initiative (EVI) and Hilleman Laboratories, announced partnership for the development of new shigella vaccine. Moreover, the EVI has received grant of US$ 9.5 Mn from the European and Developing Countries Clinical Trials Partnership (EDCTP) which aims in developing safe and effective shigella vaccine.

Also, in March 2017, Hilleman Laboratories, a non-profit organization established with joint venture partnership between Merck & Co., and Wellcome Trust has entered into an agreement with National Institute of Cholera and Enteric Disease (NICED) for the development and commercialization of vaccines against Shigella by 2024. Besides, in June 2016, Immuron- an Australian biopharmaceutical company entered into an agreement to produce Shigella vaccine with the U.S Army’s biomedical research lab-Walter Reed Army Institute of Research (WRAIR).

Prokarium and Probiomed in January 2017, collaborated to manufacture orally-administrated vaccine to prevent diarrhea. The new vaccine is expected to be manufactured as a part of two-year collaboration having thermostable capabilities for a longer period. The new vaccine is expected to be delivered to the people living in the remote areas. Thermostable vaccine, which is manufactured approximately one third of the price of the conventional injectable vaccines helps to facilities the growth of Shigella vaccines market.

The new research trial drives the Shigella vaccines market

The University Of Maryland School Of Medicine (UM SOM) in August 2017 received US$ 2.47 Million grant from the National Institute of Allergy and Infectious Diseases (NIAID) to develop vaccine against Shigella and Enterotoxigenic Escherichia coli (ETEC) for the treatment of diarrheal disease. The researchers in the UM SOM’s Center for Vaccine Development (CVD) have developed Shigella-ETEC prototype vaccine, which has been tested in animals successfully. Moreover, the latest funding helps to translate prototype to a human vaccine for Phase 1 clinical trials. Similarly, in September 2019, EveliQure Biotechnologies received grant of US$ 9,470,750 from Horizon2020 the European Union´s Research and Innovation programme, that supports the study of ShigETEC vaccine developed by EveliQure Biotechnologies

Moreover, in September 2019, LimmaTech Biologics AG and GlaxoSmithKline plc., collaboratively initiated Phase I/II clinical trial of 4-valent candidate vaccine in Kenya to prevent diarrheal disease cause due to Shigella in the developing economies.